Related Experiment Video
Updated: Jun 6, 2025
Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
Published on: September 1, 2011
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Once-Monthly versus Oral Antipsychotics in Patients with
Martha Sajatovic1, Monica Doring2, Oliver J Lopena2
1University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Purpose:
A previous integrated patient-level analysis demonstrated a significant benefit of implementing once-monthly injectable paliperidone palmitate (PP1M) earlier in the treatment course for schizophrenia. Earlier therapeutic interventions during the first 3-5 years after disease onset can positively impact long-term outcomes in schizophrenia. This present analysis evaluated the risk of relapse both overall and by different durations of illness (0-3 years, >3-5 years, and >5 years from diagnosis) in adult patients with schizophrenia who received PP1M or oral antipsychotics (OAPs).
Patients And Methods:
This analysis included integrated patient-level data from the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) and Prevention of Relapse with Oral Antipsychotics versus Injectable Paliperidone Palmitate (PROSIPAL) studies. Both studies assessed relapse as the primary outcome in patients treated either PP1M or OAPs.
Results:
Overall, the risk of relapse was reduced by 31% with PP1M compared to OAP (HR 0.69; 95% CI [0.56-0.86], P < 0.001). Fewer relapses were observed with PP1M versus OAP in the 0-3-year subgroup (15.8% and 21.7%, respectively), >3-5-year subgroup (19.6% and 29.9%, respectively), and >5-year subgroup (41.7% and 51.6%, respectively). These results represent a reduction in risk of relapse by 33% for patients receiving PP1M versus OAP in the 0-3-year subgroup (HR 0.67; 95% CI [0.44-1.00], P = 0.050), 43% in the >3-5-year subgroup (HR 0.57; 95% CI [0.35-0.93], P = 0.025), and 26% in the >5-year subgroup (HR 0.74; 95% CI [0.55-1.00], P = 0.049). Treatment-emergent adverse event rates were similar between treatment groups.
Conclusion:
This analysis indicates that PP1M provides significant benefits in reducing relapse rates compared to OAPs, regardless of the duration of illness. These findings emphasize the importance of initiating PP1M treatment early in the course of schizophrenia to achieve better long-term outcomes.
More Related Videos
06:25Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
Published on: August 12, 2019
05:52Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
01:28Psychosis and Antipsychotic Drugs: Overview
01:21Antipsychotic Drugs: Typical and Atypical Agents
01:28Drug Therapy
Antianxiety Medications
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...